Four-Repeat Tauopathies: Current Management and Future Treatments

被引:31
作者
VandeVrede, Lawren [1 ]
Ljubenkov, Peter A. [1 ]
Rojas, Julio C. [1 ]
Welch, Ariane E. [1 ]
Boxer, Adam L. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA
关键词
4R-tauopathy (4R-tau); progressive supranuclear palsy (PSP); Richardson's syndrome (PSP-RS); corticobasal syndrome (CBS); corticobasal degeneration (CBD); atypical parkinsonism; PROGRESSIVE SUPRANUCLEAR PALSY; FRONTOTEMPORAL LOBAR DEGENERATION; PLACEBO-CONTROLLED TRIAL; ANTI-TAU ANTIBODY; QUALITY-OF-LIFE; CORTICOBASAL DEGENERATION; ALZHEIMERS-DISEASE; DOUBLE-BLIND; PARKINSONS-DISEASE; DIAGNOSTIC-CRITERIA;
D O I
10.1007/s13311-020-00888-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Four-repeat tauopathies are a neurodegenerative disease characterized by brain parenchymal accumulation of a specific isoform of the protein tau, which gives rise to a wide breadth of clinical syndromes encompassing diverse symptomatology, with the most common syndromes being progressive supranuclear palsy-Richardson's and corticobasal syndrome. Despite the lack of effective disease-modifying therapies, targeted treatment of symptoms can improve quality of life for patients with 4-repeat tauopathies. However, managing these symptoms can be a daunting task, even for those familiar with the diseases, as they span motor, sensory, cognitive, affective, autonomic, and behavioral domains. This review describes current approaches to symptomatic management of common clinical symptoms in 4-repeat tauopathies with a focus on practical patient management, including pharmacologic and nonpharmacologic strategies, and concludes with a discussion of the history and future of disease-modifying therapeutics and clinical trials in this population.
引用
收藏
页码:1563 / 1581
页数:19
相关论文
共 50 条
  • [31] Current and Future Treatments in Alzheimer's Disease
    Atri, Alireza
    SEMINARS IN NEUROLOGY, 2019, 39 (02) : 227 - 240
  • [32] Current and Future Treatments of Vascular Cognitive Impairment
    Ip, Bonaventure Yiu Ming
    Ko, Ho
    Lam, Bonnie Yin Ka
    Au, Lisa Wing Chi
    Lau, Alexander Yuk Lun
    Huang, Junzhe
    Kwok, Andrew John
    Leng, Xinyi
    Cai, Yuan
    Leung, Thomas Wai Hong
    Mok, Vincent Chung Tong
    STROKE, 2024, 55 (04) : 822 - 839
  • [33] Current and Future Treatments in Primary Ciliary Dyskinesia
    Paff, Tamara
    Omran, Heymut
    Nielsen, Kim G.
    Haarman, Eric G.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [34] Current status and future prospects for biologic treatments of psoriasis
    Cline, Abigail
    Hill, Dane
    Lewallen, Robin
    Feldman, Steven R.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (12) : 1273 - 1287
  • [35] Food Allergies: Current and Future Treatments
    Licari, Amelia
    Manti, Sara
    Marseglia, Alessia
    Brambilla, Ilaria
    Votto, Martina
    Castagnoli, Riccardo
    Leonardi, Salvatore
    Marseglia, Gian Luigi
    MEDICINA-LITHUANIA, 2019, 55 (05):
  • [36] Vitiligo: Current Therapies and Future Treatments
    Seneschal, Julien
    Boniface, Katia
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2023, 13
  • [37] Current and future treatments of osteoporosis in men
    Kaufman, Jean-Marc
    Lapauw, Bruno
    Goemaere, Stefan
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 28 (06) : 871 - 884
  • [38] Pharmacological treatments for methamphetamine addiction: current status and future directions
    Ballester, Javier
    Valentine, Gerald
    Sofuoglu, Mehmet
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (03) : 305 - 314
  • [39] Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
    Loomis-King, Hillary
    Flaherty, Kevin R.
    Moore, Bethany B.
    CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 377 - 385
  • [40] Current and future treatments for relapsing-remitting multiple sclerosis
    Birnbaum, Gary
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2010, 13 (02) : 214 - 225